GSK plc (GSK.LSE) AI OPINIONS & ADVISOR ANALYSIS

The bull case activates if neladalkib clears its 27 November 2026 decision and long-acting HIV conversion visibly accelerates before generics arrive. Oncology then becomes a genuine third franchise, Nuvalent accretion pulls forward from 2029 into 2027-2028 [13], and the dolutegravir cliff flattens into a step. Each reinforces the other: credible growth beyond 2030 removes the terminal-value discount, and a low-teens multiple on rising core EPS re-rates toward mid-teens, compounding the earnings gain into materially higher shareholder returns.

The bear case activates when two independent clocks strike together: dolutegravir generics at full force and the post-2028 lapse of GSK's Section 232 exemption and pricing truce [3]. US net price erosion would then compound HIV volume loss, cost savings would be consumed rather than banked, and leverage built for Nuvalent would convert a manageable plateau into a genuine earnings decline. Progressive dividend cover tightens, the multiple compresses toward 2023's 12x trough, and investors absorb a lost half-decade.

The settled belief is that GSK is a fairly priced pharma with a known cliff: RBC's Sector Perform at 1,975 argues last year's fundamentals are already in the price, Barclays cut to 1,800, Berenberg upgraded to 2,200 [1][2]. Twenty analysts average a Neutral rating [20]. The anchoring bias is the 2028 dolutegravir date, treated as fate rather than as an already-hedged accounting event.

The crowd modestly underestimates these shares. The overlooked evidence is a guidance change, not a growth claim: GSK now expects stable-to-improving operating margins straight through the 2028-2030 dolutegravir window [9], because GBP 1.9bn of Accelerate Growth savings lands before the erosion peaks [8]. The market still prices the cliff as an unhedged earnings hole, leaving a low-teens core multiple on a business returning roughly 5% annually in cash. Statutory earnings noise from GBP 2.1bn of charges reinforces the misread [1].

The 2028 guidance frame, issued with FY2027 results in early 2028, is the trigger: the first year GSK quantifies dolutegravir erosion alongside realised cost savings. Confirmation of flat-to-up core margins would reset the cliff narrative. The first sign is a narrowing gap between core and statutory EPS.